Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $404.21 | 9 | 77.8% |
| Education | $115.26 | 2 | 22.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $242.97 | 3 | $0 (2024) |
| PFIZER INC. | $140.25 | 2 | $0 (2023) |
| Lilly USA, LLC | $44.63 | 2 | $0 (2024) |
| Galderma Laboratories, L.P. | $27.66 | 1 | $0 (2024) |
| Incyte Corporation | $24.90 | 1 | $0 (2024) |
| AbbVie Inc. | $22.32 | 1 | $0 (2020) |
| Almirall LLC | $16.74 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $115.91 | 5 | Lilly USA, LLC ($44.63) |
| 2023 | $15.27 | 1 | PFIZER INC. ($15.27) |
| 2021 | $116.73 | 2 | Regeneron Healthcare Solutions, Inc. ($99.99) |
| 2020 | $22.32 | 1 | AbbVie Inc. ($22.32) |
| 2018 | $249.24 | 2 | PFIZER INC. ($124.98) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/12/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $27.66 | General |
| 10/01/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $24.90 | General |
| Category: Dermatology | ||||||
| 09/23/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Immunology | ||||||
| 04/12/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 06/07/2021 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $99.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/02/2021 | Almirall LLC | Seysara (Drug) | Food and Beverage | Cash or cash equivalent | $16.74 | General |
| Category: Dermatology | ||||||
| 12/01/2020 | AbbVie Inc. | SKYRIZI (Biological), HUMIRA | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2018 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: DERMATOLOGY | ||||||
| 02/01/2018 | Regeneron Healthcare Solutions, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,156 | 1,896 | $401,283 | $118,265 |
| 2022 | 10 | 525 | 735 | $181,069 | $50,325 |
| 2021 | 14 | 952 | 1,403 | $330,889 | $106,556 |
| 2020 | 9 | 246 | 338 | $63,285 | $19,708 |
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 75 | 96 | $22,134 | $11,056 | 49.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 94 | 94 | $32,336 | $8,128 | 25.1% |
| 17000 | Destruction of skin growth | Office | 2021 | 113 | 141 | $27,145 | $7,184 | 26.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 25 | 34 | $15,674 | $5,733 | 36.6% |
| 12032 | Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs | Office | 2021 | 15 | 15 | $19,335 | $4,838 | 25.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $11,484 | $3,094 | 26.9% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 21 | 22 | $9,372 | $2,991 | 31.9% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 75 | 313 | $5,947 | $2,191 | 36.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 35 | 37 | $5,328 | $1,769 | 33.2% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 20 | 23 | $5,198 | $1,281 | 24.7% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 13 | 13 | $3,120 | $718.74 | 23.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 61 | 73 | $16,425 | $5,068 | 30.9% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 33 | 35 | $11,826 | $3,337 | 28.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 24 | 25 | $5,415 | $2,792 | 51.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 25 | $8,225 | $2,340 | 28.4% |
| 17000 | Destruction of skin growth | Office | 2020 | 34 | 42 | $7,922 | $2,177 | 27.5% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 28 | 28 | $6,440 | $1,789 | 27.8% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 12 | 12 | $3,960 | $1,150 | 29.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 20 | 87 | $1,566 | $556.11 | 35.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 11 | 11 | $1,507 | $498.41 | 33.1% |
About Dr. Katherine Ransohoff, M.D
Dr. Katherine Ransohoff, M.D is a Dermatology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/19/2016. The National Provider Identifier (NPI) number assigned to this provider is 1972964880.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katherine Ransohoff, M.D has received a total of $519.47 in payments from pharmaceutical and medical device companies, with $115.91 received in 2024. These payments were reported across 11 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($404.21).
As a Medicare-enrolled provider, Ransohoff has provided services to 2,879 Medicare beneficiaries, totaling 4,372 services with total Medicare billing of $294,854. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Palo Alto, CA
- Active Since 03/19/2016
- Last Updated 07/06/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1972964880
Products in Payments
- EUCRISA (Drug) $124.98
- DUPIXENT DUPILUMAB INJECTION (Biological) $124.26
- DUPIXENT (Biological) $118.71
- OPZELURA (Drug) $24.90
- TALTZ (Drug) $22.73
- SKYRIZI (Biological) $22.32
- OLUMIANT (Drug) $21.90
- Seysara (Drug) $16.74
- CIBINQO (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Palo Alto
John Doux, M.d, M.D
Dermatology — Payments: $124,944
Joyce Teng, Md, MD
Dermatology — Payments: $115,109
Shireen Guide, Md, MD
Dermatology — Payments: $79,371
Ilka Netravali, Md, MD
Dermatology — Payments: $28,025
Dr. Daniel Navi, M.d, M.D
Dermatology — Payments: $19,065
Dr. Thomas Hoffman, M.d, M.D
Dermatology — Payments: $17,860